Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21409652 | 1.00 | SHBG (0.37) | SHBGALDH1A1KMT2ACYP1A2METAP2 | |
| SCHEMBL6145227 | 0.98 | SHBG (0.41) | SHBGALDH1A1KMT2ACYP1A2METAP2 | |
| SCHEMBL6662787 | 0.98 | SHBG (0.41) | SHBGALDH1A1KMT2ACYP1A2METAP2 | |
| SCHEMBL5470740 | 0.90 | — | — | |
| SCHEMBL26668524 | 0.90 | TSHR (0.33) | SHBG | |
| SCHEMBL20354169 | 0.81 | KDM4E (0.42) | KDM4EIDO1 | |
| SCHEMBL8338960 | 0.81 | IDO1 (0.33) | KMT2AIDO1TDO2 | |
| SCHEMBL6985349 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KMT2ACYP1A2METAP2KDM4E | |
| SCHEMBL26668509 | 0.80 | TSHR (0.30) | SHBG | |
| SCHEMBL14402446 | 0.79 | ALDH1A1 (0.43) | ALDH1A1KMT2ACYP1A2METAP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088789-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2012-04-12 | — | — | US | disclosed |
| US-8153797-B2 | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-20120004257-A1 | NOVEL COMPOUNDS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| US-20100227883-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088789-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A1 | SHBG 3215/4885ALDH1A1 705/4885KMT2A 706/4885 |
| US-20120004257-A1 | NOVEL COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | SHBG 4156/4885ALDH1A1 652/4885KMT2A 906/4885 |
| US-20100227883-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC6A2, SLC18A2, SLC18A1 | SHBG 3164/4885ALDH1A1 1001/4885KMT2A 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.